Bayram Kizilkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bayram Kizilkaya has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Osman Cüre
Department of Rheumatology, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye
6 shared publications - Aleksandra Klisic
Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
3 shared publications - Filiz Mercantepe
Düzce University
3 shared publications - Hüseyin Durak
Department of Cardiology, Faculty of Medicine, Recep Tayyip Erdoğan University, 53020 Rize, Türkiye
3 shared publications - Mustafa Çetin
Department of Cardiology, Faculty of Medicine, Recep Tayyip Erdoğan University, 53020 Rize, Türkiye
3 shared publications - Ana Ninić
Department for Medical Biochemistry, University of Belgrade, Faculty of Pharmacy, Belgrade, Serbia
1 shared publication
Latest Publications
- Open Access
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7491
Association of Hemoglobin Level and Diagnostic Delay with Left Atrial Volume Index in Patients with Familial Mediterranean Fever: A Cross-Sectional Observational Study
Background/Objectives: Subclinical cardiac involvement may occur in familial Mediterranean fever, even outside acute attacks. However, the factors associated with variation in left atrial volume index (LAVI), particularly the roles of hemoglobin levels and diagnostic delay, remain poorly understood. This study aimed to evaluate the association between hemoglobin levels, diagnostic delay, and LAVI in patients with FMF. Methods: This cross-sectional observational study included 98 FMF patients with preserved left ventricular ejection fraction (LVEF ≥ 50%). Demographic, clinical, laboratory, and echocardiographic parameters were assessed. The relationships between LAVI, hemoglobin levels, and diagnostic delay were investigated using correlation analyses and multivariable linear regression. Results: Patients were 35.3 ± 12.4 years old on average, and 45.9% were men. The mean hemoglobin level, diagnostic delay, and LAVI were 13.51 ± 1.63 g/dL, 8.90 ± 9.94 years, and 18.32 ± 4.67 mL/m2, respectively. LAVI was inversely correlated with hemoglobin (r = −0.454, p < 0.001) and positively correlated with diagnostic delay (r = 0.262, p = 0.009). In the final multivariable model, hemoglobin (β = −0.333, p < 0.001), LVEF (β = 0.244, p = 0.006), and LVMI (β = 0.265, p = 0.002) were independently associated with LAVI, whereas diagnostic delay (β = 0.212, p = 0.017) and lateral a′ (β = 0.215, p = 0.014) were considered exploratory associations. Conclusions: In FMF patients, lower hemoglobin levels were independently associated with higher LAVI values, whereas diagnostic delay showed an exploratory association. These findings are hypothesis-generating and require confirmation in longitudinal studies.
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7491
Open AccessAssociation of Hemoglobin Level and Diagnostic Delay with Left Atrial Volume Index in Patients with Familial Mediterranean Fever: A Cross-Sectional Observational Study
Background/Objectives: Subclinical cardiac involvement may occur in familial Mediterranean fever, even outside acute attacks. However, the factors associated with variation in left atrial volume index (LAVI), particularly the roles of hemoglobin levels and diagnostic delay, remain poorly understood. This study aimed to evaluate the association between hemoglobin levels, diagnostic delay, and LAVI in patients with FMF. Methods: This cross-sectional observational study included 98 FMF patients with preserved left ventricular ejection fraction (LVEF ≥ 50%). Demographic, clinical, laboratory, and echocardiographic parameters were assessed. The relationships between LAVI, hemoglobin levels, and diagnostic delay were investigated using correlation analyses and multivariable linear regression. Results: Patients were 35.3 ± 12.4 years old on average, and 45.9% were men. The mean hemoglobin level, diagnostic delay, and LAVI were 13.51 ± 1.63 g/dL, 8.90 ± 9.94 years, and 18.32 ± 4.67 mL/m2, respectively. LAVI was inversely correlated with hemoglobin (r = −0.454, p < 0.001) and positively correlated with diagnostic delay (r = 0.262, p = 0.009). In the final multivariable model, hemoglobin (β = −0.333, p < 0.001), LVEF (β = 0.244, p = 0.006), and LVMI (β = 0.265, p = 0.002) were independently associated with LAVI, whereas diagnostic delay (β = 0.212, p = 0.017) and lateral a′ (β = 0.215, p = 0.014) were considered exploratory associations. Conclusions: In FMF patients, lower hemoglobin levels were independently associated with higher LAVI values, whereas diagnostic delay showed an exploratory association. These findings are hypothesis-generating and require confirmation in longitudinal studies.
- Open Access
- 22 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1252
Association Between Familial Mediterranean Fever and P-Wave Dispersion Under Colchicine Treatment
Background/Objectives: The relationship between P-wave dispersion (Pd) and disease status in patients with Familial Mediterranean Fever (FMF) undergoing colchicine treatment is unclear in the literature, and results are contradictory. This study aimed to evaluate P-wave dispersion in patients with Familial Mediterranean Fever receiving regular long-term colchicine treatment and to compare these findings with those of age- and sex-matched individuals without FMF. Methods: A cross-sectional and observational study included 97 individuals with positive FMF and 97 individuals with negative FMF. FMF diagnosis was confirmed according to the Tel-HaShomer criteria, and all patients received regular colchicine treatment and were evaluated during the attack-free period. P maximum, P minimum, and Pd were measured using standard 12-lead electrocardiography (ECG); clinical, laboratory, and drug data were recorded. Pd associations were analyzed using correlation and multivariable regression. Results: Pd was found to be significantly higher in FMF (+) patients (47 vs. 39 ms, p < 0.001). Pd showed a positive correlation with FMF status (r = 0.508, p < 0.001), colchicine dose (r = 0.476, p < 0.001), white blood cell (WBC) (r = 0.209, p = 0.005) and high-density lipoprotein cholesterol (HDL-C) (r = 0.156, p = 0.037) and a negative correlation with calcium channel blocker use (r = −0.245, p = 0.001). In multivariate analysis, FMF increased Pd by 10.17 ms, while calcium channel blockers decreased it by 11.78 ms (p < 0.001). Age, WBC and HDL-C also had independent positive effects on Pd (p < 0.001, p = 0.017, p = 0.040, respectively). Conclusions: These findings suggest that FMF is associated with increased P-wave dispersion despite regular colchicine treatment, indicating persistent subclinical atrial conduction heterogeneity.
- 22 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (9) , 1252
Open AccessAssociation Between Familial Mediterranean Fever and P-Wave Dispersion Under Colchicine Treatment
Background/Objectives: The relationship between P-wave dispersion (Pd) and disease status in patients with Familial Mediterranean Fever (FMF) undergoing colchicine treatment is unclear in the literature, and results are contradictory. This study aimed to evaluate P-wave dispersion in patients with Familial Mediterranean Fever receiving regular long-term colchicine treatment and to compare these findings with those of age- and sex-matched individuals without FMF. Methods: A cross-sectional and observational study included 97 individuals with positive FMF and 97 individuals with negative FMF. FMF diagnosis was confirmed according to the Tel-HaShomer criteria, and all patients received regular colchicine treatment and were evaluated during the attack-free period. P maximum, P minimum, and Pd were measured using standard 12-lead electrocardiography (ECG); clinical, laboratory, and drug data were recorded. Pd associations were analyzed using correlation and multivariable regression. Results: Pd was found to be significantly higher in FMF (+) patients (47 vs. 39 ms, p < 0.001). Pd showed a positive correlation with FMF status (r = 0.508, p < 0.001), colchicine dose (r = 0.476, p < 0.001), white blood cell (WBC) (r = 0.209, p = 0.005) and high-density lipoprotein cholesterol (HDL-C) (r = 0.156, p = 0.037) and a negative correlation with calcium channel blocker use (r = −0.245, p = 0.001). In multivariate analysis, FMF increased Pd by 10.17 ms, while calcium channel blockers decreased it by 11.78 ms (p < 0.001). Age, WBC and HDL-C also had independent positive effects on Pd (p < 0.001, p = 0.017, p = 0.040, respectively). Conclusions: These findings suggest that FMF is associated with increased P-wave dispersion despite regular colchicine treatment, indicating persistent subclinical atrial conduction heterogeneity.
- Open Access
- 4 April 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1)
Thyroid hormone changes after tumor necrosis factor inhibitor therapy in euthyroid patients with rheumatic diseases
Tumor necrosis factor-alpha (TNF-α) plays a central role in chronic inflammatory diseases. Anti-TNF agents are widely used in rheumatological conditio
- 4 April 2026
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 27 (1)
Open AccessThyroid hormone changes after tumor necrosis factor inhibitor therapy in euthyroid patients with rheumatic diseases
Tumor necrosis factor-alpha (TNF-α) plays a central role in chronic inflammatory diseases. Anti-TNF agents are widely used in rheumatological conditio
- Open Access
- 21 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 862
The Relationship Between Gene Subtypes, Symptoms, and Cardiac Function in Patients with Familial Mediterranean Fever
Background/Objectives: Familial Mediterranean fever (FMF) is a chronic autoinflammatory disorder that can affect cardiac structure and function. However, the impact of different Mediterranean fever (MEFV) gene subtypes on clinical features and subclinical cardiac changes remains unclear. This study aimed to evaluate the association between MEFV gene subtypes, clinical features, and cardiac function in patients with FMF. Methods: A total of 98 patients with FMF were prospectively included. Twelve mutations in the MEFV gene were screened, and the M694V homozygous (Gene-1), M694V heterozygous (Gene-2), and M680I heterozygous (Gene-3) subtypes were analyzed. All patients underwent transthoracic echocardiography and speckle-tracking strain analysis. Results: The age of disease onset was earlier in patients carrying the gene-1 mutation compared to mutation-negative patients (11.4 ± 8.0 and 17.6 ± 11.4 years, respectively; p = 0.025). Disease duration was longer in patients with gene-1 mutation (23.3 ± 12.8 and 12.5 ± 9.3 years, respectively; p < 0.001), and disease activity score was higher (6.41 ± 1.9 and 5.15 ± 1.6, respectively; p = 0.007). Furthermore, left atrial contractile strain was significantly lower in this group (−10.6 ± 3.5% and −14.5 ± 6.1%, respectively; p = 0.012). Arthralgia was more frequent in patients with gene-2 mutation (p = 0.026), while left atrial contractile strain was better preserved compared to mutation-negative patients (p = 0.002). No significant association was found between gene-3 mutation and clinical or cardiac parameters. Conclusions: MEFV gene subtypes have different effects on clinical phenotype and cardiac function in FMF. These findings support the importance of genotype-based cardiac monitoring and risk stratification in FMF patients.
- 21 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 862
Open AccessThe Relationship Between Gene Subtypes, Symptoms, and Cardiac Function in Patients with Familial Mediterranean Fever
Background/Objectives: Familial Mediterranean fever (FMF) is a chronic autoinflammatory disorder that can affect cardiac structure and function. However, the impact of different Mediterranean fever (MEFV) gene subtypes on clinical features and subclinical cardiac changes remains unclear. This study aimed to evaluate the association between MEFV gene subtypes, clinical features, and cardiac function in patients with FMF. Methods: A total of 98 patients with FMF were prospectively included. Twelve mutations in the MEFV gene were screened, and the M694V homozygous (Gene-1), M694V heterozygous (Gene-2), and M680I heterozygous (Gene-3) subtypes were analyzed. All patients underwent transthoracic echocardiography and speckle-tracking strain analysis. Results: The age of disease onset was earlier in patients carrying the gene-1 mutation compared to mutation-negative patients (11.4 ± 8.0 and 17.6 ± 11.4 years, respectively; p = 0.025). Disease duration was longer in patients with gene-1 mutation (23.3 ± 12.8 and 12.5 ± 9.3 years, respectively; p < 0.001), and disease activity score was higher (6.41 ± 1.9 and 5.15 ± 1.6, respectively; p = 0.007). Furthermore, left atrial contractile strain was significantly lower in this group (−10.6 ± 3.5% and −14.5 ± 6.1%, respectively; p = 0.012). Arthralgia was more frequent in patients with gene-2 mutation (p = 0.026), while left atrial contractile strain was better preserved compared to mutation-negative patients (p = 0.002). No significant association was found between gene-3 mutation and clinical or cardiac parameters. Conclusions: MEFV gene subtypes have different effects on clinical phenotype and cardiac function in FMF. These findings support the importance of genotype-based cardiac monitoring and risk stratification in FMF patients.
- Open Access
- 14 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7862
Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by axial skeletal involvement and systemic metabolic changes. While inflammation is central to its pathophysiology, the potential role of thyroid hormones, particularly free triiodothyronine (FT3), in disease risk and activity remains underexplored. The objective of this study is to evaluate the relationship between serum FT3 levels and both the presence and clinical activity of AS, while also examining other endocrine-metabolic parameters. In this cross-sectional study, 120 AS patients and 117 healthy controls were assessed. Demographic, anthropometric, hematologic, and biochemical parameters were recorded. Disease activity was determined using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), with BASDAI ≥ 4 indicating active disease. Logistic regression models adjusting for age, sex, BMI, and other relevant covariates were applied to identify independent predictors. FT3 levels were significantly lower in AS patients compared to controls (3.25 [3.01–3.58] vs. 3.44 [3.16–3.69] pg/mL, p = 0.037) and in patients with BASDAI ≥ 4 versus BASDAI < 4 (3.20 [2.94–3.48] vs. 3.44 [3.19–3.83] pg/mL, p = 0.004). The reduction was more evident in women, where it reflected disease presence, whereas in men it was associated with high disease activity. Low FT3 independently predicted both AS (OR 0.50, 95% CI 0.28–0.92, p = 0.026) and active disease (OR 0.48, 95% CI 0.24–0.99, p = 0.047). Lower HDL-C, BMI, and creatinine, and higher leukocyte counts were also associated with AS, but not with disease activity. Low-normal FT3 is independently associated with both the presence and activity of AS, reflecting disease presence in women and disease activity in men. This is the first study to demonstrate this sex-specific association after adjusting for metabolic parameters and multiple covariates, highlighting FT3’s potential as a marker of inflammation-driven metabolic dysregulation.
- 14 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7862
Open AccessAssociation of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by axial skeletal involvement and systemic metabolic changes. While inflammation is central to its pathophysiology, the potential role of thyroid hormones, particularly free triiodothyronine (FT3), in disease risk and activity remains underexplored. The objective of this study is to evaluate the relationship between serum FT3 levels and both the presence and clinical activity of AS, while also examining other endocrine-metabolic parameters. In this cross-sectional study, 120 AS patients and 117 healthy controls were assessed. Demographic, anthropometric, hematologic, and biochemical parameters were recorded. Disease activity was determined using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), with BASDAI ≥ 4 indicating active disease. Logistic regression models adjusting for age, sex, BMI, and other relevant covariates were applied to identify independent predictors. FT3 levels were significantly lower in AS patients compared to controls (3.25 [3.01–3.58] vs. 3.44 [3.16–3.69] pg/mL, p = 0.037) and in patients with BASDAI ≥ 4 versus BASDAI < 4 (3.20 [2.94–3.48] vs. 3.44 [3.19–3.83] pg/mL, p = 0.004). The reduction was more evident in women, where it reflected disease presence, whereas in men it was associated with high disease activity. Low FT3 independently predicted both AS (OR 0.50, 95% CI 0.28–0.92, p = 0.026) and active disease (OR 0.48, 95% CI 0.24–0.99, p = 0.047). Lower HDL-C, BMI, and creatinine, and higher leukocyte counts were also associated with AS, but not with disease activity. Low-normal FT3 is independently associated with both the presence and activity of AS, reflecting disease presence in women and disease activity in men. This is the first study to demonstrate this sex-specific association after adjusting for metabolic parameters and multiple covariates, highlighting FT3’s potential as a marker of inflammation-driven metabolic dysregulation.
- Open Access
- 11 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6064
Cardiovascular Risk in Patients with Ankylosing Spondylitis
Objectives: Ankylosing spondylitis (AS) is an autoinflammatory, chronic disease. Patients with AS are at increased risk of cardiovascular disease (CVD). The link between AS and subclinical atherosclerosis is multifactorial and still not completely understood. The aim of this study was to examine the potential associations between carotid intima–media thickness (cIMT) and different cardiometabolic biomarkers in individuals with AS. Methods: A total of 96 patients with AS were prospectively included. cIMT was measured via ultrasonography. Multiple linear regression analysis was used to find the best predictors of cIMT values. Principal component analysis (PCA) was implemented to extract factors that were further tested via binary logistic regression analysis in relation to cIMT. Results: Waist circumference (WC), low-density lipoprotein cholesterol (LDL-c), and the BASDAI score were independently correlated with cIMT in AS patients (p = 0.037, p = 0.060, and p = 0.048, respectively; adjusted R2 = 0.113). PCA extracted four panels of biomarkers, i.e., “haematology–lipid-related factor” (i.e., ferritin, haemoglobin, HDL-c, and triglycerides), “proinflammatory–prothrombotic-related factor” (i.e., platelets, neutrophils, and C-reactive protein), “LDL-c–vitamin-related factor” (i.e., vitamins D and B12, and LDL-c), and “age–glucometabolic-related factor” (i.e., age and HbA1c), in relation to higher cIMT in patients with AS. Among these four clusters, “age–glucometabolic-related factor” was an independent predictor of increased cIMT (p < 0.001). Conclusions: In addition to traditional cardiometabolic risk factors, WC and LDL-c, the disease activity score (BASDAI) is independently related to subclinical atherosclerosis in AS patients. The joint involvement of heterogeneous cardiometabolic risk factors may reflect different pathophysiological processes of subclinical atherosclerosis in patients with AS.
- 11 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6064
Open AccessCardiovascular Risk in Patients with Ankylosing Spondylitis
Objectives: Ankylosing spondylitis (AS) is an autoinflammatory, chronic disease. Patients with AS are at increased risk of cardiovascular disease (CVD). The link between AS and subclinical atherosclerosis is multifactorial and still not completely understood. The aim of this study was to examine the potential associations between carotid intima–media thickness (cIMT) and different cardiometabolic biomarkers in individuals with AS. Methods: A total of 96 patients with AS were prospectively included. cIMT was measured via ultrasonography. Multiple linear regression analysis was used to find the best predictors of cIMT values. Principal component analysis (PCA) was implemented to extract factors that were further tested via binary logistic regression analysis in relation to cIMT. Results: Waist circumference (WC), low-density lipoprotein cholesterol (LDL-c), and the BASDAI score were independently correlated with cIMT in AS patients (p = 0.037, p = 0.060, and p = 0.048, respectively; adjusted R2 = 0.113). PCA extracted four panels of biomarkers, i.e., “haematology–lipid-related factor” (i.e., ferritin, haemoglobin, HDL-c, and triglycerides), “proinflammatory–prothrombotic-related factor” (i.e., platelets, neutrophils, and C-reactive protein), “LDL-c–vitamin-related factor” (i.e., vitamins D and B12, and LDL-c), and “age–glucometabolic-related factor” (i.e., age and HbA1c), in relation to higher cIMT in patients with AS. Among these four clusters, “age–glucometabolic-related factor” was an independent predictor of increased cIMT (p < 0.001). Conclusions: In addition to traditional cardiometabolic risk factors, WC and LDL-c, the disease activity score (BASDAI) is independently related to subclinical atherosclerosis in AS patients. The joint involvement of heterogeneous cardiometabolic risk factors may reflect different pathophysiological processes of subclinical atherosclerosis in patients with AS.